Iranians improve anti-cancer delivery drug

Tehran, April 22, IRNA – Iranian researchers have improved the delivery of anti-cancer doxorubicin (DOX) drug.

Professor Davoud Habibi, a faculty member of Bu-Ali Sina University, Professor Mohammad Mostafapour-Amini, a faculty member of Shahid Beheshti University, and Sharif Kamyabi, a faculty member of Farhangian University and PhD student at Bu-Ali Sina University, conducted the study, Iran Daily reported.

The researchers encapsulated the drug in two different polymer composites (the first polymer composite: the cross-linked methacrylic modified poly N-vinyl-pyrrolidone coated magnetic nanoparticle and the second polymer composite: the cross-linked methacrylic modified poly N-isopropylacrylamide-co-N-vinylpyrrolidone coated magnetic nanoparticle.

The two composites were synthesized by the radical copolymerization of the monomers without requiring any special conditions.

Results of the study indicated the high drug loading and the low release time for the prepared composites.

When N-isopropylacrylamide was used as a monomer, the composite showed a lower critical solution temperature property that can be beneficial in cancer drug delivery, since the temperature of cancer cells is higher than normal ones and DOX can be released selectively in cancer cells.